10 |
1016/j.tins.2009.07.007.
|
[3] |
Reichling DB, Levine JD. Critical role of nociceptor plasticity
|
|
in chronic pain. Trends Neurosci, 2009, 32(12): 611-618. DOI:
|
[1] |
Goyal S, Hamrah P. Understanding neuropathic corneal pain-gaps
|
[4] |
Bignami F, Rama P, Ferrari G. Substance P and its inhibition in
|
10 |
1016/j.tins.2009.07.007.
|
|
ocular inflammation. Curr Drug Targets, 2015, 17(11): 1269-
|
|
and current therapeutic approaches. Semin Ophthalmol, 2016,
|
12 |
75. DOI: 10.2174/1389450116666151019100216.
|
31 |
(1-2): 59-70. DOI: 10.3109/08820538.2015.1114853.
|
[4] |
Bignami F, Rama P, Ferrari G. Substance P and its inhibition in
|
[5] |
Scholz J, Woolf CJ. The neuropathic pain triad: neurons,
|
[2] |
Rosenthal P, Baran I, Jacobs DS. Corneal pain without stain:
|
|
is it real. Ocul Surf, 2009, 7(1): 28-40. DOI: 10.1016/s1542-
|
|
ocular inflammation. Curr Drug Targets, 2015, 17(11): 1269-
|
12 |
75. DOI: 10.2174/1389450116666151019100216.
|
01 |
24(12)70290-2.
|
|
immune cells and glia. Nat Neurosci, 2007, 10(11): 1361-1368.
|
|
DOI: 10.1038/nn1992.
|
[5] |
Scholz J, Woolf CJ. The neuropathic pain triad: neurons,
|
[3] |
Reichling DB, Levine JD. Critical role of nociceptor plasticity
|
|
in chronic pain. Trends Neurosci, 2009, 32(12): 611-618. DOI:
|
[6] |
Flor H. Phantom-limb pain: characteristics, causes, and
|
|
treatment. Lancet Neurol, 2002, 1(3): 182-189. DOI: 10.1016/
|
|
immune cells and glia. Nat Neurosci, 2007, 10(11): 1361-1368.
|
|
DOI: 10.1038/nn1992.
|
10 |
1016/j.tins.2009.07.007.
|
|
s1474-4422(02)00074-1.
|
[6] |
Flor H. Phantom-limb pain: characteristics, causes, and
|
|
treatment. Lancet Neurol, 2002, 1(3): 182-189. DOI: 10.1016/
|
[4] |
Bignami F, Rama P, Ferrari G. Substance P and its inhibition in
|
[7] |
Mcmonnies CW. The potential role of neuropathic mechanisms
|
|
in dry eye syndromes. J Optom, 2017, 10(1): 5-13. DOI: 10.1016/
|
|
s1474-4422(02)00074-1.
|
|
j.optom.2016.06.002.
|
|
ocular inflammation. Curr Drug Targets, 2015, 17(11): 1269-
|
12 |
75. DOI: 10.2174/1389450116666151019100216.
|
[7] |
Mcmonnies CW. The potential role of neuropathic mechanisms
|
|
in dry eye syndromes. J Optom, 2017, 10(1): 5-13. DOI: 10.1016/
|
[5] |
Scholz J, Woolf CJ. The neuropathic pain triad: neurons,
|
[8] |
Rosenthal P, Borsook D. Ocular neuropathic pain. Br J
|
|
Ophthalmol, 2015, 100(1): 128-134. DOI: 10.1136/bjophthalmol-
|
|
j.optom.2016.06.002.
|
20 |
14-306280.
|
|
immune cells and glia. Nat Neurosci, 2007, 10(11): 1361-1368.
|
|
DOI: 10.1038/nn1992.
|
[8] |
Rosenthal P, Borsook D. Ocular neuropathic pain. Br J
|
|
Ophthalmol, 2015, 100(1): 128-134. DOI: 10.1136/bjophthalmol-
|
[9] |
Feng Y, Simpson TL. Characteristics of human corneal
|
|
psychophysical channels. Invest Ophthalmol Vis Sci, 2004,45(9): 3005-3010. DOI: 10.1167/iovs.04-0102.
|
20 |
14-306280.
|
[6] |
Flor H. Phantom-limb pain: characteristics, causes, and
|
|
treatment. Lancet Neurol, 2002, 1(3): 182-189. DOI: 10.1016/
|
|
s1474-4422(02)00074-1.
|
[10] |
Friedman NJ. Impact of dry eye disease and treatment on quality
|
|
of life. Curr Opin Ophthalmol, 2010, 21(4): 310-316. DOI:
|
[9] |
Feng Y, Simpson TL. Characteristics of human corneal
|
|
psychophysical channels. Invest Ophthalmol Vis Sci, 2004,45(9): 3005-3010. DOI: 10.1167/iovs.04-0102.
|
[7] |
Mcmonnies CW. The potential role of neuropathic mechanisms
|
|
in dry eye syndromes. J Optom, 2017, 10(1): 5-13. DOI: 10.1016/
|
10 |
1097/ICU.0b013e32833a8c15.
|
[11] |
刘祖国, 杨文照. 重视我国干眼的流行病学研究. 中华眼视光
|
|
学与视觉科学杂志, 2014, 16(9): 513-516. DOI: 10.3760/cma.
|
[10] |
Friedman NJ. Impact of dry eye disease and treatment on quality
|
|
of life. Curr Opin Ophthalmol, 2010, 21(4): 310-316. DOI:
|
|
j.optom.2016.06.002.
|
|
j.issn.1674-845X.2014.09.001.
|
10 |
1097/ICU.0b013e32833a8c15.
|
[11] |
刘祖国, 杨文照. 重视我国干眼的流行病学研究. 中华眼视光
|
|
学与视觉科学杂志, 2014, 16(9): 513-516. DOI: 10.3760/cma.
|
[8] |
Rosenthal P, Borsook D. Ocular neuropathic pain. Br J
|
|
Ophthalmol, 2015, 100(1): 128-134. DOI: 10.1136/bjophthalmol-
|
[12] |
Liesegang TJ. Herpes zoster ophthalmicus natural history, risk
|
|
j.issn.1674-845X.2014.09.001.
|
20 |
14-306280.
|
|
factors, clinical presentation, and morbidity. Ophthalmology,
|
20 |
08, 115(2): S3-S12. DOI: 10.1016/j.ophtha.2007.10.009.
|
[12] |
Liesegang TJ. Herpes zoster ophthalmicus natural history, risk
|
[9] |
Feng Y, Simpson TL. Characteristics of human corneal
|
|
psychophysical channels. Invest Ophthalmol Vis Sci, 2004,45(9): 3005-3010. DOI: 10.1167/iovs.04-0102.
|
[13] |
Messmer EM. Novel current and future therapy options for
|
|
factors, clinical presentation, and morbidity. Ophthalmology,
|
20 |
08, 115(2): S3-S12. DOI: 10.1016/j.ophtha.2007.10.009.
|
[10] |
Friedman NJ. Impact of dry eye disease and treatment on quality
|
|
of life. Curr Opin Ophthalmol, 2010, 21(4): 310-316. DOI:
|
[13] |
Messmer EM. Novel current and future therapy options for
|
|
treatment of dry eye disease. Ophthalmologe, 2018, 115(2): 100-
|
10 |
6. DOI: 10.1007/s00347-017-0608-6.
|
10 |
1097/ICU.0b013e32833a8c15.
|
[11] |
刘祖国, 杨文照. 重视我国干眼的流行病学研究. 中华眼视光
|
|
学与视觉科学杂志, 2014, 16(9): 513-516. DOI: 10.3760/cma.
|
|
treatment of dry eye disease. Ophthalmologe, 2018, 115(2): 100-
|
10 |
6. DOI: 10.1007/s00347-017-0608-6.
|
[14] |
Galor A, Levitt RC, Felix ER, et al. Neuropathic ocular pain:
|
|
j.issn.1674-845X.2014.09.001.
|
[14] |
Galor A, Levitt RC, Felix ER, et al. Neuropathic ocular pain:
|
|
an important yet underevaluated feature of dry eye. Eye, 2015,
|
29 |
(3): 301-312. DOI: 10.1038/eye.2014.263.
|
[12] |
Liesegang TJ. Herpes zoster ophthalmicus natural history, risk
|
[15] |
Kaido M, Kawashima M, Ishida R, et al. Relationship of corneal
|
|
an important yet underevaluated feature of dry eye. Eye, 2015,
|
29 |
(3): 301-312. DOI: 10.1038/eye.2014.263.
|
|
factors, clinical presentation, and morbidity. Ophthalmology,
|
20 |
08, 115(2): S3-S12. DOI: 10.1016/j.ophtha.2007.10.009.
|
|
pain sensitivity with dry eye symptoms in dry eye with short
|
[15] |
Kaido M, Kawashima M, Ishida R, et al. Relationship of corneal
|
[13] |
Messmer EM. Novel current and future therapy options for
|
|
pain sensitivity with dry eye symptoms in dry eye with short
|
|
tear break-up time. Invest Ophthalmol Vis Sci, 2016, 57(3): 914-
|
91 |
9. DOI: 10.1167/iovs.15-18447.
|
|
treatment of dry eye disease. Ophthalmologe, 2018, 115(2): 100-
|
10 |
6. DOI: 10.1007/s00347-017-0608-6.
|
|
tear break-up time. Invest Ophthalmol Vis Sci, 2016, 57(3): 914-
|
91 |
9. DOI: 10.1167/iovs.15-18447.
|
[16] |
Sullivan BD, Crews LA, Messmer EM, et al. Correlations
|
[14] |
Galor A, Levitt RC, Felix ER, et al. Neuropathic ocular pain:
|
[16] |
Sullivan BD, Crews LA, Messmer EM, et al. Correlations
|
|
between commonly used objective signs and symptoms for
|
|
an important yet underevaluated feature of dry eye. Eye, 2015,
|
29 |
(3): 301-312. DOI: 10.1038/eye.2014.263.
|
|
between commonly used objective signs and symptoms for
|
|
the diagnosis of dry eye disease: clinical implications. Acta
|
|
Ophthalmol, 2014, 92(2): 161-166. DOI: 10.1111/aos.12012.
|
[15] |
Kaido M, Kawashima M, Ishida R, et al. Relationship of corneal
|
|
the diagnosis of dry eye disease: clinical implications. Acta
|
|
Ophthalmol, 2014, 92(2): 161-166. DOI: 10.1111/aos.12012.
|
[17] |
Dieckmann G, Goyal S, Hamrah P. Neuropathic corneal pain:
|
|
pain sensitivity with dry eye symptoms in dry eye with short
|
[17] |
Dieckmann G, Goyal S, Hamrah P. Neuropathic corneal pain:
|
|
Approaches for management. Ophthalmology, 2017, 124(11S):
|
|
S34-S47. DOI: 10.1016/j.ophtha.2017.08.004.
|
|
tear break-up time. Invest Ophthalmol Vis Sci, 2016, 57(3): 914-
|
91 |
9. DOI: 10.1167/iovs.15-18447.
|
[18] |
Spierer O, Felix ER, McClellan AL, et al. Corneal mechanical
|
|
Approaches for management. Ophthalmology, 2017, 124(11S):
|
|
S34-S47. DOI: 10.1016/j.ophtha.2017.08.004.
|
[16] |
Sullivan BD, Crews LA, Messmer EM, et al. Correlations
|
|
thresholds negatively associate with dry eye and ocular pain
|
[18] |
Spierer O, Felix ER, McClellan AL, et al. Corneal mechanical
|
|
between commonly used objective signs and symptoms for
|
|
symptoms. Invest Ophthalmol Vis Sci, 2016, 57(2): 617-625.
|
|
DOI: 10.1167/iovs.15-18133.
|
|
thresholds negatively associate with dry eye and ocular pain
|
|
the diagnosis of dry eye disease: clinical implications. Acta
|
|
Ophthalmol, 2014, 92(2): 161-166. DOI: 10.1111/aos.12012.
|
[19] |
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II
|
|
symptoms. Invest Ophthalmol Vis Sci, 2016, 57(2): 617-625.
|
|
DOI: 10.1167/iovs.15-18133.
|
[17] |
Dieckmann G, Goyal S, Hamrah P. Neuropathic corneal pain:
|
|
definition and classification report. Ocul Surf, 2017, 15(3): 276-
|
28 |
3. DOI: 10.1016/j.jtos.2017.05.008.
|
[19] |
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II
|
|
Approaches for management. Ophthalmology, 2017, 124(11S):
|
|
S34-S47. DOI: 10.1016/j.ophtha.2017.08.004.
|
|
definition and classification report. Ocul Surf, 2017, 15(3): 276-
|
28 |
3. DOI: 10.1016/j.jtos.2017.05.008.
|
[20] |
Rosenthal P, Borsook D. The corneal pain system. Part I: the
|
[18] |
Spierer O, Felix ER, McClellan AL, et al. Corneal mechanical
|
|
missing piece of the dry eye puzzle. Ocul Surf, 2012, 10(1):
|
2- |
14. DOI: 10.1016/j.jtos.2012.01.002.
|
[20] |
Rosenthal P, Borsook D. The corneal pain system. Part I: the
|
|
thresholds negatively associate with dry eye and ocular pain
|
[21] |
Mantopoulos D, Cruzat A, Hamrah P. In vivo imaging of corneal
|
|
missing piece of the dry eye puzzle. Ocul Surf, 2012, 10(1):
|
2- |
14. DOI: 10.1016/j.jtos.2012.01.002.
|
|
symptoms. Invest Ophthalmol Vis Sci, 2016, 57(2): 617-625.
|
|
DOI: 10.1167/iovs.15-18133.
|
|
inflammation: new tools for clinical practice and research.
|
|
Semin Ophthalmol, 2010, 25(5-6): 178-185. DOI: 10.3109/
|
[21] |
Mantopoulos D, Cruzat A, Hamrah P. In vivo imaging of corneal
|
[19] |
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II
|
|
inflammation: new tools for clinical practice and research.
|
|
Semin Ophthalmol, 2010, 25(5-6): 178-185. DOI: 10.3109/
|
08 |
820538.2010.518542.
|
|
definition and classification report. Ocul Surf, 2017, 15(3): 276-
|
28 |
3. DOI: 10.1016/j.jtos.2017.05.008.
|
[22] |
Patel DV, McGhee CN. In vivo confocal microscopy of human
|
08 |
820538.2010.518542.
|
[20] |
Rosenthal P, Borsook D. The corneal pain system. Part I: the
|
|
corneal nerves in health, in ocular and systemic disease, and
|
[22] |
Patel DV, McGhee CN. In vivo confocal microscopy of human
|
|
missing piece of the dry eye puzzle. Ocul Surf, 2012, 10(1):
|
2- |
14. DOI: 10.1016/j.jtos.2012.01.002.
|
|
following corneal surgery: a review. Br J Ophthalmol, 2009,
|
93 |
(7): 853-860. DOI: 10.1136/bjo.2008.150615.
|
|
corneal nerves in health, in ocular and systemic disease, and
|
[21] |
Mantopoulos D, Cruzat A, Hamrah P. In vivo imaging of corneal
|
[23] |
Li Z, Burns AR, Han L, et al. IL-17 and VEGF are necessary for
|
|
following corneal surgery: a review. Br J Ophthalmol, 2009,
|
93 |
(7): 853-860. DOI: 10.1136/bjo.2008.150615.
|
|
inflammation: new tools for clinical practice and research.
|
|
Semin Ophthalmol, 2010, 25(5-6): 178-185. DOI: 10.3109/
|
|
efficient corneal nerve regeneration. Am J Pathol, 2011, 178(3):
|
11 |
06-1116. DOI: 10.1016/j.ajpath.2010.12.001.
|
[23] |
Li Z, Burns AR, Han L, et al. IL-17 and VEGF are necessary for
|
08 |
820538.2010.518542.
|
[24] |
Esquenazi S, Bazan HE, Bui V, et al. Topical combination of
|
|
efficient corneal nerve regeneration. Am J Pathol, 2011, 178(3):
|
11 |
06-1116. DOI: 10.1016/j.ajpath.2010.12.001.
|
[22] |
Patel DV, McGhee CN. In vivo confocal microscopy of human
|
|
NGF and DHA increases rabbit corneal nerve regeneration after
|
[24] |
Esquenazi S, Bazan HE, Bui V, et al. Topical combination of
|
|
corneal nerves in health, in ocular and systemic disease, and
|
|
photorefractive keratectomy. Invest Ophthalmol Vis Sci, 2005,
|
46 |
(9): 3121-3127. 77. DOI: 10.1167/iovs.05-0241.
|
|
NGF and DHA increases rabbit corneal nerve regeneration after
|
|
following corneal surgery: a review. Br J Ophthalmol, 2009,
|
93 |
(7): 853-860. DOI: 10.1136/bjo.2008.150615.
|
[25] |
He J, Cortina MS, Kakazu A, et al. The PEDF neuroprotective
|
|
photorefractive keratectomy. Invest Ophthalmol Vis Sci, 2005,
|
46 |
(9): 3121-3127. 77. DOI: 10.1167/iovs.05-0241.
|
[23] |
Li Z, Burns AR, Han L, et al. IL-17 and VEGF are necessary for
|
|
domain plus DHA induces corneal nerve regeneration after
|
[25] |
He J, Cortina MS, Kakazu A, et al. The PEDF neuroprotective
|
|
efficient corneal nerve regeneration. Am J Pathol, 2011, 178(3):
|
11 |
06-1116. DOI: 10.1016/j.ajpath.2010.12.001.
|
|
domain plus DHA induces corneal nerve regeneration after
|
|
experimental surgery. Invest Ophthalmol Vis Sci, 2015, 56(6):
|
35 |
05-3513. DOI: 10.1167/iovs.15-16755.
|
[24] |
Esquenazi S, Bazan HE, Bui V, et al. Topical combination of
|
|
experimental surgery. Invest Ophthalmol Vis Sci, 2015, 56(6):
|
35 |
05-3513. DOI: 10.1167/iovs.15-16755.
|
[26] |
Sarkar J, Chaudhary S, Namavari A, et al. Corneal neurotoxicity
|
|
NGF and DHA increases rabbit corneal nerve regeneration after
|
[26] |
Sarkar J, Chaudhary S, Namavari A, et al. Corneal neurotoxicity
|
|
due to topical benzalkonium chloride. Invest Ophthalmol Vis
|
|
Sci, 2012, 53(4): 1792-1802. DOI: 10.1167/iovs.11-8775.
|
|
photorefractive keratectomy. Invest Ophthalmol Vis Sci, 2005,
|
46 |
(9): 3121-3127. 77. DOI: 10.1167/iovs.05-0241.
|
[27] |
Cirillo, Cavaliere G, Bianco C, et al. Intrathecal NGF
|
|
due to topical benzalkonium chloride. Invest Ophthalmol Vis
|
|
Sci, 2012, 53(4): 1792-1802. DOI: 10.1167/iovs.11-8775.
|
[25] |
He J, Cortina MS, Kakazu A, et al. The PEDF neuroprotective
|
|
administration reduces reactive astrocytosis and changes
|
[27] |
Cirillo, Cavaliere G, Bianco C, et al. Intrathecal NGF
|
|
domain plus DHA induces corneal nerve regeneration after
|
|
neurotrophin receptors expression pattern in a rat model of
|
|
neuropathic pain. Cell Mol Neurobiol, 2010, 30(1): 51-62. DOI:
|
|
administration reduces reactive astrocytosis and changes
|
|
experimental surgery. Invest Ophthalmol Vis Sci, 2015, 56(6):
|
35 |
05-3513. DOI: 10.1167/iovs.15-16755.
|
10 |
1007/s10571-009-9430-2.
|
|
neurotrophin receptors expression pattern in a rat model of
|
|
neuropathic pain. Cell Mol Neurobiol, 2010, 30(1): 51-62. DOI:
|
[26] |
Sarkar J, Chaudhary S, Namavari A, et al. Corneal neurotoxicity
|
[28] |
Aggarwal S, Kheirkhah A, Cavalcanti BM, et al. Autologous
|
10 |
1007/s10571-009-9430-2.
|
|
due to topical benzalkonium chloride. Invest Ophthalmol Vis
|
|
Sci, 2012, 53(4): 1792-1802. DOI: 10.1167/iovs.11-8775.
|
|
serum tears for treatment of photoallodynia in patients with
|
[28] |
Aggarwal S, Kheirkhah A, Cavalcanti BM, et al. Autologous
|
[27] |
Cirillo, Cavaliere G, Bianco C, et al. Intrathecal NGF
|
|
corneal neuropathy: efficacy and evaluation with in vivo
|
|
confocal microscopy. Ocul Surf, 2015, 13(3): 250-262. DOI:
|
|
serum tears for treatment of photoallodynia in patients with
|
|
administration reduces reactive astrocytosis and changes
|
10 |
1016/j.jtos.2015.01.005.
|
|
corneal neuropathy: efficacy and evaluation with in vivo
|
|
confocal microscopy. Ocul Surf, 2015, 13(3): 250-262. DOI:
|
|
neurotrophin receptors expression pattern in a rat model of
|
|
neuropathic pain. Cell Mol Neurobiol, 2010, 30(1): 51-62. DOI:
|
[29] |
Coffey MJ, Decory HH, Lane SS. Development of a
|
10 |
1016/j.jtos.2015.01.005.
|
|
non-settling gel formulation of 0.5% loteprednol etabonate for
|
10 |
1007/s10571-009-9430-2.
|
[29] |
Coffey MJ, Decory HH, Lane SS. Development of a
|
|
anti-inflammatory use as an ophthalmic drop. Clin Ophthalmol,
|
20 |
13, 7(2): 299-312. DOI: 10.2147/OPTH.S40588.
|
|
non-settling gel formulation of 0.5% loteprednol etabonate for
|
[30] |
Solomon KD. Comparison of ketorolac tromethamine 0.5%
|
|
and loteprednol etabonate 0.5% for inflammation after
|
[28] |
Aggarwal S, Kheirkhah A, Cavalcanti BM, et al. Autologous
|
|
anti-inflammatory use as an ophthalmic drop. Clin Ophthalmol,
|
20 |
13, 7(2): 299-312. DOI: 10.2147/OPTH.S40588.
|
[30] |
Solomon KD. Comparison of ketorolac tromethamine 0.5%
|
|
phacoemulsification: Prospective randomized double-masked
|
|
study. J Cataract Refract Surg, 2002, 28(1): 93-99. DOI:
|
|
and loteprednol etabonate 0.5% for inflammation after
|
|
serum tears for treatment of photoallodynia in patients with
|
10 |
1016/s0886-3350(01)01185-3.
|
|
phacoemulsification: Prospective randomized double-masked
|
|
study. J Cataract Refract Surg, 2002, 28(1): 93-99. DOI:
|
|
corneal neuropathy: efficacy and evaluation with in vivo
|
|
confocal microscopy. Ocul Surf, 2015, 13(3): 250-262. DOI:
|
[31] |
Kheirkhah A, Dohlman TH, Amparo F, et al. Effects of corneal
|
10 |
1016/s0886-3350(01)01185-3.
|
|
nerve density on the response to treatment in dry eye disease.
|
|
Ophthalmology, 2015, 122(4): 662-668. DOI: 10.1016/j.ophtha.
|
10 |
1016/j.jtos.2015.01.005.
|
[31] |
Kheirkhah A, Dohlman TH, Amparo F, et al. Effects of corneal
|
|
nerve density on the response to treatment in dry eye disease.
|
|
Ophthalmology, 2015, 122(4): 662-668. DOI: 10.1016/j.ophtha.
|
[29] |
Coffey MJ, Decory HH, Lane SS. Development of a
|
20 |
14.11.006.
|
|
non-settling gel formulation of 0.5% loteprednol etabonate for
|
20 |
14.11.006.
|
[32] |
Mick G, Correaillanes G. Topical pain management with the
|
|
anti-inflammatory use as an ophthalmic drop. Clin Ophthalmol,
|
20 |
13, 7(2): 299-312. DOI: 10.2147/OPTH.S40588.
|
[30] |
Solomon KD. Comparison of ketorolac tromethamine 0.5%
|
|
and loteprednol etabonate 0.5% for inflammation after
|
[32] |
Mick G, Correaillanes G. Topical pain management with the
|
5% |
lidocaine medicated plaster-a review. Curr Medi Res Opin,
|
20 |
12, 28(6): 937-951. DOI: 10.1185/03007995.2012.690339.
|
|
phacoemulsification: Prospective randomized double-masked
|
|
study. J Cataract Refract Surg, 2002, 28(1): 93-99. DOI:
|
[33] |
Moscovici BK, Holzchuh R, Sakassegawa-Naves FE, et al.
|
10 |
1016/s0886-3350(01)01185-3.
|
5% |
lidocaine medicated plaster-a review. Curr Medi Res Opin,
|
20 |
12, 28(6): 937-951. DOI: 10.1185/03007995.2012.690339.
|
|
Treatment of Sjögren’s syndrome dry eye using 0.03%
|
[33] |
Moscovici BK, Holzchuh R, Sakassegawa-Naves FE, et al.
|
|
tacrolimus eye drop: prospective double-blind randomized study.
|
|
Cont Lens Anterior Eye, 2015, 8(5): 373-378. DOI: 10.1016/
|
[31] |
Kheirkhah A, Dohlman TH, Amparo F, et al. Effects of corneal
|
|
Treatment of Sjögren’s syndrome dry eye using 0.03%
|
|
nerve density on the response to treatment in dry eye disease.
|
|
Ophthalmology, 2015, 122(4): 662-668. DOI: 10.1016/j.ophtha.
|
|
tacrolimus eye drop: prospective double-blind randomized study.
|
|
Cont Lens Anterior Eye, 2015, 8(5): 373-378. DOI: 10.1016/
|
|
j.clae.2015.04.004.
|
20 |
14.11.006.
|
|
j.clae.2015.04.004.
|
[34] |
Dastjerdi MH, Hamrah P, Dana R. High-frequency topical
|
|
cyclosporine 0.05% in the treatment of severe dry eye refractory
|
|
to twice-daily regimen. Cornea, 2009, 28(10): 1091-1096. DOI:
|
[32] |
Mick G, Correaillanes G. Topical pain management with the
|
[34] |
Dastjerdi MH, Hamrah P, Dana R. High-frequency topical
|
|
cyclosporine 0.05% in the treatment of severe dry eye refractory
|
|
to twice-daily regimen. Cornea, 2009, 28(10): 1091-1096. DOI:
|
10 |
1097/ICO.0b013e3181a16472.
|
5% |
lidocaine medicated plaster-a review. Curr Medi Res Opin,
|
20 |
12, 28(6): 937-951. DOI: 10.1185/03007995.2012.690339.
|
10 |
1097/ICO.0b013e3181a16472.
|
[35] |
Moscovici BK, Holzchuh R, Chiacchio BB, et al. Clinical
|
|
treatment of dry eye using 0.03% tacrolimus eye drops. Cornea,
|
20 |
12, 31(8): 945-949. DOI: 10.1097/ICO.0b013e31823f8c9b.
|
[33] |
Moscovici BK, Holzchuh R, Sakassegawa-Naves FE, et al.
|
|
Treatment of Sjögren’s syndrome dry eye using 0.03%
|
[35] |
Moscovici BK, Holzchuh R, Chiacchio BB, et al. Clinical
|
|
treatment of dry eye using 0.03% tacrolimus eye drops. Cornea,
|
20 |
12, 31(8): 945-949. DOI: 10.1097/ICO.0b013e31823f8c9b.
|
[36] |
Amparo F, Dastjerdi MH, Okanobo A, et al. Topical interleukin
|
|
tacrolimus eye drop: prospective double-blind randomized study.
|
|
Cont Lens Anterior Eye, 2015, 8(5): 373-378. DOI: 10.1016/
|
[36] |
Amparo F, Dastjerdi MH, Okanobo A, et al. Topical interleukin
|
1 |
receptor antagonist for treatment of dry eye disease: a
|
|
j.clae.2015.04.004.
|
1 |
receptor antagonist for treatment of dry eye disease: a
|
|
randomized clinical trial. JAMA Ophthalmol, 2013, 131(6):
|
71 |
5-723. DOI: 10.1001/jamaophthalmol.2013.195.
|
[34] |
Dastjerdi MH, Hamrah P, Dana R. High-frequency topical
|
|
cyclosporine 0.05% in the treatment of severe dry eye refractory
|
|
to twice-daily regimen. Cornea, 2009, 28(10): 1091-1096. DOI:
|
|
randomized clinical trial. JAMA Ophthalmol, 2013, 131(6):
|
71 |
5-723. DOI: 10.1001/jamaophthalmol.2013.195.
|
[37] |
Abidi A, Shukla P, Ahmad A. Lifitegrast: A novel drug for
|
10 |
1097/ICO.0b013e3181a16472.
|
[37] |
Abidi A, Shukla P, Ahmad A. Lifitegrast: A novel drug for
|
|
treatment of dry eye disease. J Pharmaco Thera, 2016, 7(4): 194-
|
19 |
8. DOI: 10.4103/0976-500X.195920.
|
[35] |
Moscovici BK, Holzchuh R, Chiacchio BB, et al. Clinical
|
|
treatment of dry eye using 0.03% tacrolimus eye drops. Cornea,
|
20 |
12, 31(8): 945-949. DOI: 10.1097/ICO.0b013e31823f8c9b.
|
|
treatment of dry eye disease. J Pharmaco Thera, 2016, 7(4): 194-
|
19 |
8. DOI: 10.4103/0976-500X.195920.
|
[38] |
Ervin AM, Law A, Pucker AD. Punctal occlusion for dry eye
|
[36] |
Amparo F, Dastjerdi MH, Okanobo A, et al. Topical interleukin
|
[38] |
Ervin AM, Law A, Pucker AD. Punctal occlusion for dry eye
|
|
syndrome. Cochrane Database Syst Rev, 2017, 6: CD006775.
|
|
DOI: 10.1002/14651858.CD006775.pub3.
|
[39] |
Geerling G, Tost FH. Surgical occlusion of the lacrimal drainagesystem. Dev Ophthalmol, 2008, 41(41): 213-229. DOI: 10.1159/
|
1 |
receptor antagonist for treatment of dry eye disease: a
|
00 |
0131091.
|
|
syndrome. Cochrane Database Syst Rev, 2017, 6: CD006775.
|
|
DOI: 10.1002/14651858.CD006775.pub3.
|
[39] |
Geerling G, Tost FH. Surgical occlusion of the lacrimal drainagesystem. Dev Ophthalmol, 2008, 41(41): 213-229. DOI: 10.1159/
|
|
randomized clinical trial. JAMA Ophthalmol, 2013, 131(6):
|
71 |
5-723. DOI: 10.1001/jamaophthalmol.2013.195.
|
00 |
0131091.
|
[40] |
Qiao J, Yan X. Emerging treatment options for meibomian gland
|
|
dysfunction. Clin Ophthalmol, 2013, 7(9): 1797-1803. DOI:
|
[37] |
Abidi A, Shukla P, Ahmad A. Lifitegrast: A novel drug for
|
[40] |
Qiao J, Yan X. Emerging treatment options for meibomian gland
|
|
dysfunction. Clin Ophthalmol, 2013, 7(9): 1797-1803. DOI:
|
10 |
2147/OPTH.S33182.
|
|
treatment of dry eye disease. J Pharmaco Thera, 2016, 7(4): 194-
|
19 |
8. DOI: 10.4103/0976-500X.195920.
|
10 |
2147/OPTH.S33182.
|
[41] |
Toyos R, McGill W, Briscoe D. Intense pulsed light treatment
|
[38] |
Ervin AM, Law A, Pucker AD. Punctal occlusion for dry eye
|
|
for dry eye disease due to meibomian gland dysfunction; a
|
[41] |
Toyos R, McGill W, Briscoe D. Intense pulsed light treatment
|
|
syndrome. Cochrane Database Syst Rev, 2017, 6: CD006775.
|
|
DOI: 10.1002/14651858.CD006775.pub3.
|
[39] |
Geerling G, Tost FH. Surgical occlusion of the lacrimal drainagesystem. Dev Ophthalmol, 2008, 41(41): 213-229. DOI: 10.1159/
|
3- |
year retrospective study. Photomed Laser Surg, 2015, 33(1):
|
41 |
-46. DOI: 10.1089/pho.2014.3819.
|
|
for dry eye disease due to meibomian gland dysfunction; a
|
00 |
0131091.
|
[42] |
Thode AR, Latkany RA. Current and emerging therapeutic
|
3- |
year retrospective study. Photomed Laser Surg, 2015, 33(1):
|
41 |
-46. DOI: 10.1089/pho.2014.3819.
|
[40] |
Qiao J, Yan X. Emerging treatment options for meibomian gland
|
|
dysfunction. Clin Ophthalmol, 2013, 7(9): 1797-1803. DOI:
|
|
strategies for the treatment of meibomian gland dysfunctio
|
(MGD) |
Drugs, 2015, 75(11): 1177-1185. DOI: 10.1007/s40265-
|
[42] |
Thode AR, Latkany RA. Current and emerging therapeutic
|
10 |
2147/OPTH.S33182.
|
01 |
5-0432-8.
|
|
strategies for the treatment of meibomian gland dysfunctio
|
(MGD) |
Drugs, 2015, 75(11): 1177-1185. DOI: 10.1007/s40265-
|
[41] |
Toyos R, McGill W, Briscoe D. Intense pulsed light treatment
|
[43] |
Dimit R, Gire A, Pflugfelder SC, et al. Patient ocular conditions
|
01 |
5-0432-8.
|
|
for dry eye disease due to meibomian gland dysfunction; a
|
|
and clinical outcomes using a PROSE scleral device. Cont Lens
|
|
Anterior Eye, 2013, 36(4): 159-163. DOI: 10.1016/j.clae.2013.
|
[43] |
Dimit R, Gire A, Pflugfelder SC, et al. Patient ocular conditions
|
02 |
004.
|
3- |
year retrospective study. Photomed Laser Surg, 2015, 33(1):
|
41 |
-46. DOI: 10.1089/pho.2014.3819.
|
|
and clinical outcomes using a PROSE scleral device. Cont Lens
|
|
Anterior Eye, 2013, 36(4): 159-163. DOI: 10.1016/j.clae.2013.
|
[44] |
Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic
|
02 |
004.
|
[42] |
Thode AR, Latkany RA. Current and emerging therapeutic
|
|
neuralgia: epidemiology, pathophysiology, and pain management
|
|
pharmacology. J Multidiscip Healthc, 2016, 9(9): 447-454. DOI:
|
[44] |
Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic
|
|
strategies for the treatment of meibomian gland dysfunctio
|
(MGD) |
Drugs, 2015, 75(11): 1177-1185. DOI: 10.1007/s40265-
|
01 |
5-0432-8.
|
10 |
2147/JMDH.S106340.
|
|
neuralgia: epidemiology, pathophysiology, and pain management
|
|
pharmacology. J Multidiscip Healthc, 2016, 9(9): 447-454. DOI:
|
[43] |
Dimit R, Gire A, Pflugfelder SC, et al. Patient ocular conditions
|
[45] |
Derry S, Wiffen PJ, Aldington D, et al. Nortriptyline for
|
10 |
2147/JMDH.S106340.
|
|
and clinical outcomes using a PROSE scleral device. Cont Lens
|
|
Anterior Eye, 2013, 36(4): 159-163. DOI: 10.1016/j.clae.2013.
|
|
neuropathic pain in adults. Cochrane Database Syst Rev, 2015,
|
1: |
CD011209. DOI: 10.1002/14651858.CD011209.pub2.
|
[45] |
Derry S, Wiffen PJ, Aldington D, et al. Nortriptyline for
|
02 |
004.
|
[46] |
Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic
|
|
neuropathic pain in adults. Cochrane Database Syst Rev, 2015,
|
1: |
CD011209. DOI: 10.1002/14651858.CD011209.pub2.
|
[44] |
Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic
|
|
management of neuropathic pain: evidence-based recommendations.
|
|
Pain, 2007, 132(3): 237-251. DOI: 10.1016/j.pain.2007.08.033.
|
[46] |
Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic
|
|
neuralgia: epidemiology, pathophysiology, and pain management
|
|
pharmacology. J Multidiscip Healthc, 2016, 9(9): 447-454. DOI:
|
[47] |
Gilron I, Tu D, Holden RR, et al. Combination of morphine with
|
|
management of neuropathic pain: evidence-based recommendations.
|
|
Pain, 2007, 132(3): 237-251. DOI: 10.1016/j.pain.2007.08.033.
|
10 |
2147/JMDH.S106340.
|
|
nortriptyline for neuropathic pain. Pain, 2015, 156(8): 1440-
|
14 |
48. DOI: 10.1097/j.pain.0000000000000149.
|
[47] |
Gilron I, Tu D, Holden RR, et al. Combination of morphine with
|
[45] |
Derry S, Wiffen PJ, Aldington D, et al. Nortriptyline for
|
[48] |
Sidhu HS, Sadhotra A. Current status of the new antiepileptic
|
|
nortriptyline for neuropathic pain. Pain, 2015, 156(8): 1440-
|
14 |
48. DOI: 10.1097/j.pain.0000000000000149.
|
|
neuropathic pain in adults. Cochrane Database Syst Rev, 2015,
|
1: |
CD011209. DOI: 10.1002/14651858.CD011209.pub2.
|
|
drugs in chronic pain. Front Pharmacol, 2016, 7(8): 276-291.
|
|
DOI: 10.3389/fphar.2016.00276.
|
[48] |
Sidhu HS, Sadhotra A. Current status of the new antiepileptic
|
[46] |
Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic
|
[49] |
Jorns TP, Zakrzewska JM. Evidence-based approach to the
|
|
drugs in chronic pain. Front Pharmacol, 2016, 7(8): 276-291.
|
|
DOI: 10.3389/fphar.2016.00276.
|
|
management of neuropathic pain: evidence-based recommendations.
|
|
Pain, 2007, 132(3): 237-251. DOI: 10.1016/j.pain.2007.08.033.
|
|
medical management of trigeminal neuralgia. Br J Neurosurg,
|
20 |
07, 21(3): 253-261. DOI: 10.1080/02688690701219175.
|
[49] |
Jorns TP, Zakrzewska JM. Evidence-based approach to the
|
[47] |
Gilron I, Tu D, Holden RR, et al. Combination of morphine with
|
[50] |
Grace PM, Fabisiak TJ, Green-Fulgham SM, et al. Prior
|
|
medical management of trigeminal neuralgia. Br J Neurosurg,
|
20 |
07, 21(3): 253-261. DOI: 10.1080/02688690701219175.
|
|
nortriptyline for neuropathic pain. Pain, 2015, 156(8): 1440-
|
14 |
48. DOI: 10.1097/j.pain.0000000000000149.
|
|
voluntary wheel running attenuates neuropathic pain. Pain, 2016,
|
15 |
7(9): 2012-2023. DOI: 10.1097/j.pain.0000000000000607.
|
[50] |
Grace PM, Fabisiak TJ, Green-Fulgham SM, et al. Prior
|
[48] |
Sidhu HS, Sadhotra A. Current status of the new antiepileptic
|
[51] |
Allen NE, Moloney N, Vliet VV, et al. The Rationale for
|
|
voluntary wheel running attenuates neuropathic pain. Pain, 2016,
|
15 |
7(9): 2012-2023. DOI: 10.1097/j.pain.0000000000000607.
|
|
drugs in chronic pain. Front Pharmacol, 2016, 7(8): 276-291.
|
|
DOI: 10.3389/fphar.2016.00276.
|
|
Exercise in the Management of Pain in Parkinson’s Disease.
|
|
J Parkinsons Dis, 2015, 5(2): 229-239. DOI: 10.3233/JPD-
|
14 |
0508.
|
[51] |
Allen NE, Moloney N, Vliet VV, et al. The Rationale for
|
[49] |
Jorns TP, Zakrzewska JM. Evidence-based approach to the
|
|
Exercise in the Management of Pain in Parkinson’s Disease.
|
|
J Parkinsons Dis, 2015, 5(2): 229-239. DOI: 10.3233/JPD-
|
[52] |
Liu A, Ji J. Omega-3 essential fatty acids therapy for dry eye
|
14 |
0508.
|
|
medical management of trigeminal neuralgia. Br J Neurosurg,
|
20 |
07, 21(3): 253-261. DOI: 10.1080/02688690701219175.
|
|
syndrome: a meta-analysis of randomized controlled studies.
|
|
Med Sci Monit, 2014, 20: 1583-1589. DOI: 10.12659/MSM.
|
89 |
1364.
|
[52] |
Liu A, Ji J. Omega-3 essential fatty acids therapy for dry eye
|
[50] |
Grace PM, Fabisiak TJ, Green-Fulgham SM, et al. Prior
|
|
syndrome: a meta-analysis of randomized controlled studies.
|
|
Med Sci Monit, 2014, 20: 1583-1589. DOI: 10.12659/MSM.
|
[53] |
Lefaucheur JP. rTMS in the Treatment of Neuropathic Pain//
|
89 |
1364.
|
|
voluntary wheel running attenuates neuropathic pain. Pain, 2016,
|
15 |
7(9): 2012-2023. DOI: 10.1097/j.pain.0000000000000607.
|
|
Therapeutic rTMS in Neurology. Springer International
|
|
Publishing, 2016. DOI: 10.1007/s00520-016-3177-3.
|
[53] |
Lefaucheur JP. rTMS in the Treatment of Neuropathic Pain//
|
[51] |
Allen NE, Moloney N, Vliet VV, et al. The Rationale for
|
|
Exercise in the Management of Pain in Parkinson’s Disease.
|
|
J Parkinsons Dis, 2015, 5(2): 229-239. DOI: 10.3233/JPD-
|
[54] |
Majithia N, Smith TJ, Coyne PJ, et al. Scrambler Therapy for
|
|
Therapeutic rTMS in Neurology. Springer International
|
|
Publishing, 2016. DOI: 10.1007/s00520-016-3177-3.
|
14 |
0508.
|
|
the management of chronic pain. Supportive Care in Cancer,
|
20 |
16, 24(6): 2807-2814. DOI: 10.1007/s00520-016-3177-3.
|
[54] |
Majithia N, Smith TJ, Coyne PJ, et al. Scrambler Therapy for
|
[52] |
Liu A, Ji J. Omega-3 essential fatty acids therapy for dry eye
|
|
syndrome: a meta-analysis of randomized controlled studies.
|
|
Med Sci Monit, 2014, 20: 1583-1589. DOI: 10.12659/MSM.
|
|
the management of chronic pain. Supportive Care in Cancer,
|
20 |
16, 24(6): 2807-2814. DOI: 10.1007/s00520-016-3177-3.
|
89 |
1364.
|
[53] |
Lefaucheur JP. rTMS in the Treatment of Neuropathic Pain//
|
|
Therapeutic rTMS in Neurology. Springer International
|
|
Publishing, 2016. DOI: 10.1007/s00520-016-3177-3.
|
[54] |
Majithia N, Smith TJ, Coyne PJ, et al. Scrambler Therapy for
|
|
the management of chronic pain. Supportive Care in Cancer,
|
20 |
16, 24(6): 2807-2814. DOI: 10.1007/s00520-016-3177-3.
|